EPTIFIBATIDE News
EPTIFIBATIDE currently has 2 news articles, with 11 predicted indications.
This page combines the AI-predicted indications for EPTIFIBATIDE with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Evidence level: L5
- Predicted indications (11):
- acute coronary syndrome (99.0%)
- rheumatoid arthritis (100.0%)
- sickle cell-hemoglobin d disease syndrome (100.0%)
- sickle cell-hemoglobin E disease syndrome (100.0%)
- sickle cell-hemoglobin c disease syndrome (100.0%)
- hereditary persistence of fetal hemoglobin-sickle cell disease syndrome (100.0%)
- sickle cell-beta-thalassemia disease syndrome (100.0%)
- hemoglobinopathy (100.0%)
- female breast carcinoma (100.0%)
- beta-thalassemia with other manifestations (100.0%)
- partial deletion of the short arm of chromosome 16 (100.0%)
Related News (2)
From wrist to research: Harnessing smartwatch data for equitable cardiovascular research
2026-09-28 cardiovascular
Source: journals.plos.org
Conference MDAngle: HFSA 2026 Amyloidosis/ATTR-CM
2026-09-28 heart disease
Source: Medscape
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.